Abstract
No public abstract is available from the verified source records.
Katherine Xiaoyan Zhong, Runying Long, Jiangnan He, Ruiqian Zhang, Ling Shan Hung, Can Cui, Cheng Bao, Crystal Tang, Zhangping Xiao, Michelle Kwan Yee Siu, Tina Na Wei, Stephanie Si Liu, Kui Liu, Bryan Cho Wing Li, Haonan Lu, Karen Kar Loen Chan
Abstract
Authors
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Mirvetuximab soravtansine in FRα-positive, platinum-resistant ovarian cancer
10.1056/nejmoa2309169 · 2023
Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: Results from the SORAYA Study
10.1200/jco.22.01900 · 2023
10.1038/s41568-026-00916-0
10.1038/s41568-026-00916-0
Enfortumab vedotin in previously treated advanced urothelial carcinoma
10.1056/nejmoa2035807 · 2021
Enfortumab vedotin antibody-drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models
10.1158/0008-5472.can-15-1313 · 2016
10.1038/s41568-021-00388-4
10.1038/s41568-021-00388-4
10.1038/s41416-019-0650-z
10.1038/s41416-019-0650-z
10.1038/s41571-021-00470-8
10.1038/s41571-021-00470-8
10.1158/2767-9764.crc-24-0093
10.1158/2767-9764.crc-24-0093
10.1158/2767-9764.crc-24-0435
10.1158/2767-9764.crc-24-0435
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
doaj
Confidence 92%
datacite
Confidence 0%
No additional external references are available.